• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
186006 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

! H9 L+ T/ N6 P6 @! {# j7 T可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
& M; W6 S1 w  `1 h$ _# M
. L* W2 u# ~! @' i% i1 a
; e4 E8 Y& ^) ]& SSub-category:" |0 x0 D; ^2 Q' B) `4 \
Molecular Targets * I7 i# E& X9 @$ g* ~' o* \. b
4 o. i1 a( O. C' A. C* {" s0 i' o

" i; J' g# `( Q$ E0 G9 xCategory:
4 C( \8 I# V( J1 cTumor Biology
% ?* ]7 D1 ~/ s  h5 l2 f) B: ]2 Q2 q' M( J1 J9 p4 ^+ \
0 o8 I* Q0 A  M' i' M3 x
Meeting:
0 X% H8 W- f: X1 z2011 ASCO Annual Meeting
7 {. _+ A8 r2 @& K# \& X
8 D9 _8 a+ m6 ]" {8 G/ D. s+ m2 |7 L$ Q% q6 q1 I, N
Session Type and Session Title:' z+ \6 |- d  A$ [0 [4 a! P- H# _
Poster Discussion Session, Tumor Biology ) |) I$ t2 B7 E6 k$ J7 S
0 d9 C! }8 {- d

1 m: A7 y! t8 SAbstract No:
5 o8 ^4 k4 t' ?4 }6 A( L& h10517
1 v9 J( P# r! T  N4 f: M8 K0 @1 g$ D. J; O. C- [$ l% w/ b5 O7 \

# b# y% M; B! P* p" KCitation:
! E' U6 M2 B0 P( r3 y; W  o6 SJ Clin Oncol 29: 2011 (suppl; abstr 10517) ! N+ x5 w+ |4 C
4 l+ ?2 Q: x: `4 m

9 V9 G# Q  s5 R$ cAuthor(s):
7 _2 I! b3 `! yJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
! b/ ^" V; D2 D0 R4 p
8 ]7 K  r; {5 [7 a; L
+ o6 `$ \5 Q. t0 m! G3 x( V- a2 l' \
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.# h, ~. A/ _0 E  G0 F' ]

' k7 v# s. g2 b* E" a; |, GAbstract Disclosures
, @) M) c- m  r* B; E- p
( k: @: O- }. H5 R8 f3 QAbstract:
5 i1 I; P4 t3 }7 O+ b
1 R! x+ p8 \. r  Z: L" W1 `% V7 w5 N2 O' {& Z
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 A  B* E- f/ W) E; G& i# k- R. a3 f

5 \. u) n: [/ U; l1 l5 g1 v* M
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
4 g8 a. H5 H. e- W/ u' n没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

  a% i, m; C( a- ^/ c! r/ I化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
4 S! s6 n6 y& C7 z0 ]( k易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。# A) z3 S$ A$ }+ F8 d
ALK一个指标医院要900多 ...
7 z4 w8 E0 q/ |" e' R
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?: C+ Y7 P3 @. m* }) C
3 o; g5 ^6 ?# P: a- i3 P
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表